evaluation of sd-208, a tgf-β-ri kinase inhibitor, as an anticancer agent in retinoblastoma
Authors
abstract
retinoblastoma is the most common intraocular tumor in children resulting from genetic alterations and transformation of mature retinal cells. the objective of this study was to investigate the effects of sd-208, tgf-β-ri kinase inhibitor, on the expression of some mirnas including a mir-17/92 cluster in retinoblastoma cells. prior to initiate this work, the cell proliferation was studied by methyl thiazolyl tetrazolium (mtt) and bromo-2′-deoxyuridine (brdu) assays. then, the expression patterns of four mirnas (18a, 20a, 22, and 34a) were investigated in the treated sd-208 (0.0, 1, 2 and 3 µm) and untreated y-79 cells. a remarkable inhibition of the cell proliferation was found in y-79 cells treated with sd-208 versus untreated cells. also, the expression changes were observed in mirnas 18a, 20a, 22 and 34a in response to sd-208 treatment ( p <0.05). the findings of the present study suggest that the anti-cancer effect of sd-208 may be exerted due to the regulation of specific mirnas, at least in this particular retinoblastoma cell line. to the best of the researchers’ knowledge, this is the first report demonstrating that the sd-208 could alter the expression of tumor suppressive mirnas as well as oncomirs in vitro. in conclusion, the present data suggest that sd-208 could be an alternative agent in retinoblastoma treatment.
similar resources
Evaluation of SD-208, a TGF-β-RI Kinase Inhibitor, as an Anticancer Agent in Retinoblastoma.
Retinoblastoma is the most common intraocular tumor in children resulting from genetic alterations and transformation of mature retinal cells. The objective of this study was to investigate the effects of SD-208, TGF-β-RI kinase inhibitor, on the expression of some miRNAs including a miR-17/92 cluster in retinoblastoma cells. Prior to initiate this work, the cell proliferation was studied by Me...
full textDown-regulation of miR-135b in colon adenocarcinoma induced by a TGF-β receptor I kinase inhibitor (SD-208)
Objective(s):Transforming growth factor-β(TGF-β) is involved in colorectal cancer (CRC). The SD-208 acts as an anti-cancer agent in different malignancies via TGF-β signaling. This work aims to show the effect of manipulation of TGF-β signaling on some miRNAs implicated in CRC. Materials and Methods: We investigated the effects of SD-208 on SW-48, a colon adenocarcinoma cell line. The cell li...
full textdown-regulation of mir-135b in colon adenocarcinoma induced by a tgf-β receptor i kinase inhibitor (sd-208)
objective(s):transforming growth factor-β(tgf-β) is involved in colorectal cancer (crc). the sd-208 acts as an anti-cancer agent in different malignancies via tgf-β signaling. this work aims to show the effect of manipulation of tgf-β signaling on some mirnas implicated in crc. materials and methods: we investigated the effects of sd-208 on sw-48, a colon adenocarcinoma cell line. the cell line...
full textDown-regulation of miR-135b in colon adenocarcinoma induced by a TGF-β receptor I kinase inhibitor (SD-208)
OBJECTIVES Transforming growth factor-β (TGF-β) is involved in colorectal cancer (CRC). The SD-208 acts as an anti-cancer agent in different malignancies via TGF-β signaling. This work aims to show the effect of manipulation of TGF-β signaling on some miRNAs implicated in CRC. MATERIALS AND METHODS We investigated the effects of SD-208 on SW-48, a colon adenocarcinoma cell line. The cell line...
full text2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent
2-Hydroxypropyl-β-cyclodextrin (HP-β-CyD) is a cyclic oligosaccharide that is widely used as an enabling excipient in pharmaceutical formulations, but also as a cholesterol modifier. HP-β-CyD has recently been approved for the treatment of Niemann-Pick Type C disease, a lysosomal lipid storage disorder, and is used in clinical practice. Since cholesterol accumulation and/or dysregulated cholest...
full textEvaluation of Fetal Toxicity of HESA-A, a Natural Anticancer Agent, in Mice
Introduction: HESA-A is an active natural compound with herbal and marine origin. It contains inorganic, organic and aqueous fractions, and has shown antioxidant, cytotoxic and anticancer effects. In this study, the teratogenic effects of HESA-A in mice have been evaluated. Methods: Several doses of HESA-A were administered orally to pregnant mice on days 6 to 14 of gestation. Various parameter...
full textMy Resources
Save resource for easier access later
Journal title:
acta medica iranicaجلد ۵۴، شماره ۶، صفحات ۳۵۲-۳۵۸
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023